Nexpowder
MarketedPowder endoscopic haemostat; cumulative sales to Q3 2026 were about KRW 11.9 billion, with exports split 51% US, 42% Europe and 7% Japan.
FROM PUBLIC EVENTS · 2026-11-18
Global approvals · expansion Earns most haemostat revenue from exports to the US, Europe and Japan while running a US approval trial for its embolic agent. Also seen: Early clinical · first deals
Roles often seen at this stageDevice R&D & support · Regulatory affairs · Clinical & PV
A developer of polymer medical devices and drug delivery technology that makes the Nexpowder endoscopic haemostat and Nexsphere embolic agents, earning about 97% of revenue overseas.
Powder endoscopic haemostat; cumulative sales to Q3 2026 were about KRW 11.9 billion, with exports split 51% US, 42% Europe and 7% Japan.
Embolic agents whose cumulative sales to Q3 2026 rose 25% year on year; Nexsphere-F is in a clinical trial for US FDA approval.
A next-generation haemostat adding chemical coagulation to physical adhesion, to go through a Korean trial before a US FDA IDE application.
Reported record quarterly revenue of about KRW 5.2 billion for Q3 2026.
Started government-backed projects to develop the Nexpowder T haemostat and to test the Nexsphere-H embolic in musculoskeletal pain patients.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.